Search Browse Earnings

Taysha Gene Therapies, Inc.

Nasdaq:TSHA

Biological Products, (No Diagnostic Substances)·DALLAS, TX

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$15.5M

+517.5% YoY

FY 2024

Adj. EBITDA

-$71.1M

-460.0% margin

FY 2024

Net Income

-$111.6M

-722.1% margin

FY 2024

EPS (Diluted)

-$0.96

FY 2024

Stock Price

$4.49

-2.6%

2026-03-13

52W Range

$1.05 – $6.02

P/E Ratio

-4.7x

Market Cap

$1.2B

Cash

$143.9M

FY 2024

Total Debt

$40.5M

FY 2024

Net Cash

$103.4M

FY 2024

Enterprise Value

$1.1B

Debt / EBITDA

1.5x

FY 2024

EV / EBITDA

-15.9x

Employees

—